# Oral Supplementation of Gangliosides to Treat a Rare Metabolic Disorder

> **NCT02234024** · NA · UNKNOWN · sponsor: **DDC Clinic - Center for Special Needs Children** · enrollment: 20 (estimated)

## Conditions studied

- GM3 Synthase Deficiency

## Interventions

- **DIETARY_SUPPLEMENT:** Supplementation of dairy-derived concentrated gangliosides.

## Key facts

- **NCT ID:** NCT02234024
- **Lead sponsor:** DDC Clinic - Center for Special Needs Children
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02234024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02234024, "Oral Supplementation of Gangliosides to Treat a Rare Metabolic Disorder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02234024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*